Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
Natera and Guardant are about to shake things up with indication-specific blood tests, but Exact is keeping faith with Cologuard – for now.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
The liquid biopsy era is finally here.
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.